Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
The most compelling fundamental opportunity lies in the rapid execution of the Profit Recovery and Growth Plan (PRGP) converting Estée Lauder's exceptional 75.50% gross margin into double-digit operating margin expansion.
Consolidated operating margin remaining below 7.50% over the next 12 months, or China geographic revenue declining below $3,500M.
We assign a Sell rating to The Estée Lauder Companies Inc. with a Fair value of $51.63 per share, representing 43.86% downside from the share price of $91.97 as of October 2, 2026.4
Our Sell rating indicates that investors should avoid initiating new positions and trim or eliminate existing holdings in Estée Lauder. For ordinary investors, this recommendation reflects a substantial valuation disconnect: prevailing share prices demand flawless multi-year operational execution, leaving capital heavily exposed to any delay in margin recovery or further Chinese consumption softness.
As of October 2, 2026, Estée Lauder shares closed at $91.97. Our disciplined fundamental valuation establishes a Fair value midpoint of $51.63 per share, indicating an implied downside return of -43.86%, or a 78.13% price premium above fair value. Even against our optimistic Potential value ceiling of $69.17 per share—which presumes rapid restructuring success—the share price of $91.97 as of October 2, 2026 trades at an expansive 32.96% premium, providing no margin of safety.4
The primary risk that could alter our cautious view is a failure of operational restructuring and persistent luxury demand stagnation that drives shares even further below our Fair value. Specifically, if fixed SG&A commitments of $9,685M cannot be restructured while promotional discounting continues in Asian travel retail, operating margin remaining trapped below 7.50% (versus 5.18% in FY2026) would truncate forward EPS well below consensus expectations of $3.32 in FY2027. Paired with $9,246M in total balance sheet debt and an elevated 6.80% pre-tax cost of debt, refinancing strains would compound earnings erosion.12457
Conversely, the principal operational catalyst that could drive fundamental value toward our Potential value of $69.17 is the successful execution of the Profit Recovery and Growth Plan alongside rapid travel retail restocking. Estée Lauder generates an exceptional 75.50% gross margin from its prestige brand portfolio ($11,362M gross profit on $15,049M revenue in FY2026,). If overhead rationalization successfully delivers management's raised operating margin target of 12.7% to 13.5%, while Hainan retail shipments recover strictly to demand, powerful operating leverage would expand diluted EPS toward consensus estimates of $3.91 by FY2028, boosting operating cash flow well above trailing levels of $1,773M.
Estée Lauder generates industry-leading gross margins of 75.50% ($11,362M gross profit on $15,049M revenue in FY2026,), significantly exceeding peers like Colgate-Palmolive at 60.43% and Procter & Gamble at 50.87%. As the Profit Recovery and Growth Plan reduces non-consumer overhead, modest volume gains translate into rapid operating margin expansion toward management's 12.7%–13.5% guidance range.357
We rate Estée Lauder a Sell because the prevailing share price of $91.97 embeds an aggressive, flawless operational turnaround that trades at an unsustainable 78.13% premium to fundamental Fair value of $51.63,.4
The Estée Lauder Companies Inc. is a global leader in prestige beauty, engaged in the manufacturing, marketing, and sale of quality skin care, makeup, fragrance, and hair care products. Its portfolio features globally recognized brands including Estée Lauder, Clinique, M·A·C, and The Ordinary,. The company distributes its products across an integrated omnichannel ecosystem consisting of specialty-multi retailers such as Sephora, upscale department stores, freestanding brand stores, travel retail corridors, and digital social commerce channels.
The company serves diverse global markets across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. In fiscal year 2026, Estée Lauder generated $15,049M in consolidated net revenue, with geographic contributions including $3,749M from the United States (24.9% of net sales), $3,930M from China (26.1% of net sales), and $7,370M from other international geographies.
In an acute macroeconomic stress scenario combining extended consumer retrenchment in Greater China with structural cost rigidity in North America, Estee Lauder's financial profile faces severe impairment. If China revenue contracts by 15% from the FY2026 level of $3,930M to $3,340M, and US net sales stagnate below $3,700M, total net sales would fall below $14,500M. Under such top-line pressure, if fixed SG&A expenses cannot be reduced below $9,200M due to retail store lease commitments, advertising retainers, and counter staffing overhead, operating income would drop toward $400M, compressing operating margin to under 3.0%. With annual net interest expense of $334M on $9,246M of total debt and an elevated pre-tax cost of debt at 6.80%, pre-tax earnings would be nearly eliminated. Under this stress test, free cash flow conversion would deteriorate, turning cash flow insufficient to sustain the $1.40 annual dividend without drawing down the $3,498M cash balance, precipitating severe toward historical consumer distressed multiples and placing equity value near the lowest valuation boundary.
The Estee Lauder Companies possesses a narrow economic moat rooted in its portfolio of premier prestige beauty brands and extensive global omnichannel distribution infrastructure. Across core skincare, makeup, fragrance, and hair care categories, brand equity built over decades allows the company to command substantial pricing power, as evidenced by a consolidated gross margin of 75.50% in FY2026 ($11,362M gross profit on $15,049M revenue,). This gross margin level dramatically exceeds consumer defensive peers such as Colgate-Palmolive at 60.43%, Kenvue at 58.44%, and Procter & Gamble at 50.87%, highlighting strong structural pricing power and consumer willingness to pay for premium formulations.
However, Estee Lauder's competitive moat has narrowed significantly due to severe operational and friction. The company's fixed operating cost structure—characterized by $9,685M in SG&A expenses in FY2026—severely eroded to $780M, compressing to 5.18%. Unlike peers who maintain between 19.0% and 22.1%, Estee Lauder's heavy reliance on department store beauty counters, high marketing retainers, and concession staffing has created structural operating drag. Consequently, declined to 5.30%, falling below its computed cost of capital of 8.4628% and destroying at the trough of the cycle.
The highlighted cell is Fair value when every assumption sits at its base level ($51.63). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $824.4M after modeled reinvestment of $274.8M, with terminal value at 78.5% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to , reinvestment, or resets materially.
Accelerating operating margin expansion beyond preliminary guidance accompanied by sustained volume growth in Greater China would demonstrate faster restructuring execution, closing the operating profitability gap with peers and justifying a less negative stance.
Personal care industry capital expenditures track at 1.10% of revenue and capex to depreciation stands at 1.07x. Estee Lauder incurred $457M in capex in FY2026 (3.04% of revenue) against $796M in depreciation, resulting in a capex-to-depreciation ratio of 0.57x. Because capacity additions are asset-light and lead times are short, the beauty cycle is primarily demand-led and evidence-limited regarding physical capacity constraints.7
Upside cyclical drivers in prestige beauty are propelled by global travel normalization, premiumization trends in active skincare, duty-free policy incentives in destinations like Hainan, and expanding middle-class beauty consumption across emerging markets. In an upswing, operating leverage on fixed retail concessions drives rapid margin expansion.
Downside cyclical pressures stem from structural macroeconomic deceleration in Greater China, consumer trade-down behavior, and the aftermath of inventory over-shipments into travel retail duty-free corridors. When regional consumer sentiment weakens and travel retail channels experience inventory gluts, promotional discounting and inventory write-downs erode profitability across the luxury personal care sector.
Under the house Sell rating, an equity position sizing of 0% is recommended. The share price of $91.97 reflects an implied return of -43.86% to our Fair value of 51.63, representing a 78.13% price premium. The risk-reward balance remains unfavorable, warranting complete capital redeployment away from EL shares.4
Risk management mandates strict capital protection against high valuation vulnerability. Estee Lauder trades at 29.76x forward P/E while carrying $9,246M in total balance sheet debt with pre-tax cost of debt at 6.80% in a 5.24% risk-free rate environment. Equity holders face substantial downside risk if operational turnaround execution lags consensus expectations. Existing positions should be divested on share price strength, and new capital should remain sidelined until shares re-price toward fundamental fair value.
At $91.97, shares trade at a 78.13% premium to Fair value ($51.63) and an elevated forward P/E of 29.76x compared to peer multiples of 12.6x to 20.5x,. Value investors should avoid the stock due to the lack of margin of safety and wait for multiple compression toward historical peer medians.34
Although management targets top-line stabilization and share gains in China, consensus revenue growth is modest at 4.46% in FY2027 and 4.28% in FY2028. Growth investors face substantial downside risk if Chinese consumer demand decelerates further, leaving little upside catalyst relative to the demanding .
We recommend a Sell on The Estée Lauder Companies Inc. at the share price of $91.97 as of October 2, 2026. Our fundamental valuation indicates a Fair value of $51.63, implying -43.86% downside return. The market's valuation multiple of 29.76x forward P/E trades at an untenable premium relative to defensive consumer peers (13.9x–20.5x,), demanding an aggressive operational turnaround that leaves no margin for error.34
While Estée Lauder retains premier brand intangibles and a 75.50% gross margin, FY2026 operating margin collapsed to 5.18% under elevated SG&A expenses. With $9,246M in debt and substantial exposure to Chinese consumer sentiment ($3,930M in FY2026), risk-adjusted returns heavily favor reallocating capital to higher-conviction consumer defensive peers until valuation aligns with normalized earnings power.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Channel destocking across Hainan and broader Asian travel retail corridors is reaching completion, with management shifting to a strict ship-to-demand posture. Travel retail returned to positive sales exiting FY2026, while six consecutive quarters of market share gains in China help stabilize the $3,930M Chinese revenue base.58
Despite trough GAAP net income of $182M in FY2026, Estée Lauder generated $1,773M in operating cash flow and $1,316M in free cash flow against capital expenditures of $457M. This strong cash conversion supports the annual dividend commitment and funds operational turnaround investments without dilutive equity issuance.467
Downside risk manifests if Chinese luxury consumer demand suffers persistent structural stagnation and local C-beauty competitors continue eroding market share, while US department store traffic declines accelerate. Inability to flex down fixed SG&A expenses traps operating margins below target levels, leaving diluted earnings constrained and forcing significant multiple contraction toward peer averages as debt refinancing costs mount.
FY2026 operating margin compressed to 5.18% ($780M operating income on $15,049M revenue,). If restructuring fails to flex down fixed SG&A commitments and promotional discounting continues in Asia travel retail, operating margin remaining below 7.5% would severely truncate forward EPS below consensus ($3.32 in FY2027).157
China generated $3,930M in FY2026 (26.1% of revenue). A contraction below $3,500M would falsify the travel retail recovery thesis and break consensus FY2028 revenue projections of $16,393M.158
EL currently trades at 29.76x forward P/E, whereas peers trade much lower: Colgate-Palmolive at 20.55x, Procter & Gamble at 19.58x, and Kenvue at 13.87x. With $9,246M of total debt and pre-tax cost of debt at 6.80%, failure to de-lever forces terminal multiple compression toward peers.234
The five developments that would weaken our investment case.
Indicates restructuring failure under the Profit Recovery and Growth Plan, where rigid SG&A commitments prevent translation of gross profit into operating profit.
Current:5.18% in FY2026
Alert ifOperating margin remaining below 7.50% in FY2027
Falsifies the travel retail inventory replenishment thesis and reflects severe luxury demand erosion alongside market share loss to domestic C-beauty competitors.
Current:$3,930M in FY2026
Alert ifChina geographic revenue falling below $3,500M
Loss of market confidence in earnings turnaround timing while carrying $9,246M of total debt at a 6.80% pre-tax cost of debt.
Current:29.76x forward P/E as of 2026-10-03
Alert ifDe-rating toward peer median forward P/E of 18.00x-20.00x
Demonstrates that omnichannel expansion into specialty multi and social commerce has failed to offset persistent foot traffic declines in traditional department stores.
Current:$3,749M in FY2026
Alert ifNegative YoY revenue growth (< 0.0%) in FY2027
Rising debt refinancing burden in a higher-for-longer interest rate regime (pre-tax debt cost 6.80%), restricting cash flow flexibility and endangering capital returns.
Current:$9,246M total debt in FY2026
Alert ifTotal debt exceeding $9,500M or trailing net debt reduction below $500M
The durability of Estee Lauder's moat is further tested in its core growth markets. In Greater China, which accounted for $3,930M or 26.1% of consolidated net sales in FY2026, post-pandemic inventory accumulation in Hainan travel retail triggered extensive destocking and discounting. Concurrently, agile local Chinese brands (C-beauty) have gained market share in mass-to-prestige price points through rapid product iteration and direct social commerce execution. While Estee Lauder has countered with six consecutive quarters of market share gains in China and expanded specialty-multi distribution in the US, its economic moat remains bounded until restructuring structurally lowers SG&A expenses and restores returns on capital above WACC.
In FY2026, Estee Lauder generated an economic loss as return on invested capital fell to 5.30% compared to a computed cost of capital (WACC) of 8.4628%, representing a negative economic spread of -3.16 percentage points. Consolidated operating income of $780M on revenue of $15,049M resulted in an operating margin of 5.18%, sharply below peer Colgate-Palmolive at 20.97% and Procter & Gamble at 22.09%. While operating cash flow of $1,773M and free cash flow of $1,316M demonstrate ongoing cash generation capability, invested capital productivity remains impaired by $9,246M in total balance sheet debt and bloated working capital cycles across Asian travel retail channels. Sustainable economic profit creation requires expanding operating margins back toward the 12.7%–13.5% management target.234567
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Solve for the growth rate that makes the model value equal the report-date share price.
The modal expected path reflects gradual operational recovery under the Profit Recovery and Growth Plan, with FY2027 net sales growing 4.46% to $15,720M and FY2028 revenue expanding 4.28% to $16,393M. Operating margin normalizes from 5.18% in FY2026 to 9.20% in FY2027 and reaches 13.50% at the forecast horizon. Diluted EPS expands from trough GAAP $0.50 to $3.32 in FY2027 and $3.91 in FY2028. Discounted at an 8.46% WACC and 9.81% cost of equity, the fundamental composite fair value resolves to Fair value $51.63.127
Upside optionality materializes if Hainan and Asian travel retail channels restock faster than expected, accelerating China revenue above historical baseline trends while M·A·C and prestige skincare drive mid-single-digit growth in the US. In this scenario, fixed SG&A leverage accelerates operating margin expansion by FY2028, pushing diluted EPS toward the high end of consensus ($4.30) and generating robust annual free cash flow, supporting valuation toward Potential value $69.17.1
Meeting preliminary guidance confirms that operational recovery is under way but leaves the share price at $91.97 substantially above the house Fair value of $51.63, confirming that valuation remains stretched.
Operating margin compression or renewed sales contraction in Asia travel retail reveals structural cost rigidity and persistent luxury demand softness, confirming the primary downside thesis.
Reported earnings quality reflects an inflection point where cash conversion significantly outperforms GAAP net income. Free cash flow generation driven by working capital discipline and channel inventory normalization provides solid support for underlying operations, while discrete restructuring charges and non-operating tax items have temporarily depressed GAAP net income. Gross margin stability across flagship prestige skincare and makeup lines demonstrates durable core pricing power, confirming that bottom-line depression stems primarily from operating overhead rather than fundamental product obsolescence.
Reveals whether restructuring initiatives under the Profit Recovery and Growth Plan are successfully scaling down non-consumer facing expenses, which determines whether operating profit can rebound toward peer levels.
Signals whether channel destocking has concluded and wholesalers are resuming orders, directly dictating shipment volume, gross profit conversion, and Asian regional revenue.
Indicates brand equity strength relative to domestic competitors in mainland China, determining sustainable long-term revenue growth and pricing power in a primary profit center.
Shows whether expansion into specialty multi and social commerce can offset foot traffic erosion in department stores, stabilizing domestic volume throughput.
Dictates whether cash generation can comfortably service debt obligations in a higher interest rate regime, fund restructuring commitments, and support the dividend.
| $17.74B |
| $15.91B |
| $15.61B |
| $14.33B |
| $15.05B |
| -4.0% |
| Gross profit | $13.43B | $11.35B | $11.18B | $10.60B | $11.36B | -4.1% |
| Operating income | $3.17B | $1.51B | $970.0M | $-785.0M | $780.0M | -29.6% |
| Net income | $2.39B | $1.01B | $390.0M | $-1.13B | $182.0M | -47.5% |
| EPS (diluted) | $6.55 | $2.79 | $1.08 | $-3.15 | $0.50 | -47.4% |
| EBITDA | $3.93B | $2.40B | $1.98B | $146.0M | $1.65B | -19.5% |
| R&D | $307.0M | $344.0M | $360.0M | $316.0M | — | +1.0% |
| SG&A | $9.89B | $9.58B | $9.62B | $9.46B | $9.69B | -0.5% |
Cash flow conversion represents a critical operational pillar. Despite GAAP net income compressing to $182M in FY2026, operating cash flow remained robust at $1,773M. Non-cash depreciation and amortization of $796M and working capital normalization supported cash generation. Free cash flow of $1,316M represented an 8.7% free cash flow margin on $15,049M revenue, providing adequate self-funding to finance the Profit Recovery and Growth Plan without requiring emergency equity issuance.467
Estee Lauder's capital allocation reflects the constraints of an operational trough. In FY2026, the company generated $1,773M in operating cash flow and directed $457M to capital expenditures, leaving $1,316M in free cash flow. However, capital allocation flexibility is severely restricted by $9,246M in total balance sheet debt ($5,748M net debt against $3,498M cash). In a high interest rate regime with a 5.24% risk-free rate and a 6.80% pre-tax cost of debt, debt servicing costs absorb substantial cash flow. With the annual dividend of $1.40 per share representing a 2.80x payout ratio on FY2026 GAAP of $0.50, management must prioritize debt reduction and organic turnaround investments over share repurchases.
Estee Lauder's ROIC collapsed to 5.30% in FY2026, dropping sharply from peak historical levels (17.87% in FY2022) due to operating income compression to $780M and Hainan channel destocking. Invested capital remains burdened by $9,246M in total debt. As the Profit Recovery and Growth Plan expands operating margin toward the 12.7%–13.5% guidance range, ROIC is projected to rebound above WACC toward 10.5%–12.0% by FY2029, though near-term capital returns remain cyclically depressed.
FY2026 ROIC of 5.30% trails the computed WACC of 8.4628%, generating a negative spread of -3.16 percentage points during the earnings trough.
Estee Lauder generated a 75.50% gross margin in FY2026 ($11,362M gross profit on $15,049M revenue,), significantly outpacing Colgate-Palmolive at 60.43% and peer benchmark averages of 51.04%. However, SG&A expenses of $9,685M consumed 64.36% of sales, compressing operating margin to 5.18% ($780M operating income) versus peer operating margins of 19.0%–22.1%.
Operating expense leverage is the single most critical driver of intrinsic value; scaling down corporate overhead via the Profit Recovery and Growth Plan unlocks massive earnings growth without needing aggressive top-line acceleration.
Consolidated GAAP net income fell to $182M in FY2026 ($0.50 EPS), but operating cash flow reached $1,773M and free cash flow reached $1,316M, supported by disciplined capex of $457M.
GAAP earnings significantly overstate the business's liquidity distress, as cash flow conversion remains healthy and capable of self-funding operational turnaround initiatives.
EL shares trade at a forward P/E of 29.76x, compared to Colgate-Palmolive at 20.55x, Procter & Gamble at 19.58x, and Kenvue at 13.87x.
At $91.97 per share, the market is already pricing in an aggressive, flawless earnings recovery, leaving equity valuation highly vulnerable to multiple de-rating if restructuring hits bottlenecks.
| Revenue | $15,049,000,000 |
|---|---|
| Cost of revenue | $3,687,000,000 |
| Gross profit | $11,362,000,000 |
| Operating expenses | $10,582,000,000 |
| Operating income | $780,000,000 |
| Non-operating items and tax | -$598,000,000 |
| Net income | $182,000,000 |
| Total assets | $19,762,000,000 |
|---|---|
| Cash | $3,498,000,000 |
| Current assets | $7,612,000,000 |
| Total liabilities | $15,956,000,000 |
| Current liabilities | $6,231,000,000 |
| Shareholders’ equity | $3,806,000,000 |
| Net income | $182,000,000 |
|---|---|
| Operating inflow | $1,773,000,000 |
| Depreciation and amortization | $796,000,000 |
| Stock-based compensation | $310,000,000 |
| Other operating adjustments | $485,000,000 |
| Operating cash flow | $1,773,000,000 |
| Cash available | $4,699,000,000 |
| Beginning cash | $2,921,000,000 |
| Exchange-rate effect | $5,000,000 |
| Investing outflow | $489,000,000 |
| Capex | $457,000,000 |
| Other investing activities | $32,000,000 |
| Financing outflow | $712,000,000 |
| Share repurchases | $70,000,000 |
| Dividends paid | $508,000,000 |
| Net debt repayment | $3,000,000 |
| Other financing activities | $131,000,000 |
| Ending cash | $3,498,000,000 |
| Investing cash flow | -$489,000,000 |
| Financing cash flow | -$712,000,000 |
Source: SEC EDGAR · Filed 2026-08-19 · SEC EDGAR
| Revenue by geography | Revenue | Share | YoY |
|---|---|---|---|
| Other | $7.4B | 49% | 6.6% |
| China | $3.9B | 26.1% | 7.6% |
| United States | $3.7B | 24.9% | -0.3% |
Point-in-time financial data used in the 2026-10-03 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-06-30 | $11.8B | $2.2B | — | $1.8B | $1.3B | $504M | $464M | $219M | $413M | $486M | — | -$2.2B | $630M | — | $1.1B | $1.7B | $3.6B | 14.4% | — | 5.3% | — |
| 2018-06-30 | $13.7B | $2.6B | $1.1B | $2.6B | $1.9B | $629M | $531M | $236M | $759M | $546M | — | -$358M | -$1.2B | $1.1B | $2.2B | $2.7B | $3.5B | 15.0% | — | 5.8% | — |
| 2019-06-30 | $14.9B | $3B | $1.8B | $2.5B | $1.8B | $744M | $557M | $243M | $1.6B | $609M | — | $473M | -$2.2B | $2.2B | $3B | $3B | $3.4B | 15.6% | — | 5.3% | — |
| 2020-06-30 | $14.3B | $1.8B | $684M | $2.3B | $1.7B | $623M | $611M | $213M | $893M | $503M | — | -$1.7B | $1.5B | $3B | $5B | $5B | $8.8B | 4.2% | — | 3.8% | — |
| 2021-06-30 | $16.2B | $4.2B | $2.9B | $3.6B | $3B | $637M | $651M | $327M | $733M | $753M | — | -$1.9B | -$1.9B | $5B | $5B | $5B | $8.1B | 16.1% | — | 4.6% | — |
| 2022-06-30 | $17.7B | $3.9B | $2.4B | $3B | $2B | $1B | $727M | $331M | $2.3B | $840M | -$22M | -$945M | -$3B | $5B | $4B | $4B | $7.6B | 17.9% | — | 6.2% | — |
| 2023-06-30 | $15.9B | $2.4B | $1B | $1.7B | $728M | $1B | $744M | $267M | $271M | $925M | $2.7B | -$3.2B | $1.6B | $4B | $4B | $4B | $10.2B | 9.5% | — | 6.8% | — |
| 2024-06-30 | $15.6B | $2B | $390M | $2.4B | $1.4B | $919M | $825M | $325M | $35M | $947M | -$362M | -$960M | -$2B | $4B | $3.4B | $3.4B | $9.8B | 6.2% | — | 6.9% | — |
| 2025-06-30 | $14.3B | $146M | -$1.1B | $1.3B | $670M | $602M | $829M | $304M | $35M | $618M | -$505M | -$623M | -$1.1B | $3.4B | $2.9B | $2.9B | $9.5B | -5.5% | — | — | — |
| 2026-06-30 | $15B | $1.6B | $182M | $1.8B | $1.3B | $457M | $796M | $310M | $70M | $508M | -$3M | -$489M | -$712M | $2.9B | $3.5B | $3.5B | $9.2B | 5.2% | — | 7.8% | — |
The Estee Lauder Companies Inc. (EL) trades at 29.8x forward earnings against a peer median of 16.7x. Its EV/EBITDA of 15.9x compares with a peer median of 13.2x. The comparison uses 4 peers: Colgate-Palmolive Company, The Procter & Gamble Company, Kenvue Inc. and Kimberly-Clark Corporation, as of 2026-10-03.
Estee Lauder occupies an operationally levered position at the cyclical trough. Its high gross margin (75.50% in FY2026) provides immense theoretical flow-through as volumes recover, but its heavy exposure to China (26.1% of revenue at $3,930M) leaves it more cyclically exposed than diversified consumer defensive peers such as Procter & Gamble and Colgate-Palmolive.78
| Level | Action | Why |
|---|---|---|
| Below $51.63 (Fair Value Midpoint) | Re-evaluate fundamental turnaround progress | A price decline to or below our Fair value of 51.63 eliminates the market valuation premium, warranting re-assessment of restructuring milestones. |
| Below $40.00 (Margin of Safety Threshold) | Evaluate selective speculative accumulation | Provides an adequate margin of safety relative to the dedicated Section 2 Bear scenario, conditional upon verified stabilization in Asia travel retail and net debt reduction. |
While free cash flow of $1,316M in FY2026 supports dividend continuity, trailing GAAP net income of $182M leaves the dividend payout ratio heavily stretched at 2.80x. With $9,246M in debt requiring cash flow for debt service at 6.80% interest, dividend growth is likely frozen, making alternative consumer staples far more attractive.246
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Discounted forecast-period cash flows ($12.87) plus discounted terminal value ($47.10) minus signed net debt per current share ($15.86) equals the $44.11 lens value shown above. Negative net debt is net cash, so subtracting it raises value.
| PG |
| The Procter & Gamble Company |
| $336.8B |
| 19.6x |
| 3.9x |
| 14.7x |
| 30.3% |
| 22.1% |
| KVUE | Kenvue Inc. | $33.0B | 13.9x | 2.1x | 11.6x | 15.6% | 19.4% |
| KMB | Kimberly-Clark Corporation | $31.3B | 12.6x | 1.9x | 10.7x | 104.9% | 19.0% |
